AESKU.GROUP GmbH

Wendelsheim based AESKU.GROUP, composed of AESKU.DIAGNOSTICS, AESKU.SYSTEMS, AESKU.KIPP INSTITUTE, AESKU.THERAPY, DST & AESKU.BION, offers the most comprehensive product portfolio in the field of autoimmune diagnostic - worldwide. AESKU.GROUP is proud to provide its state-of-the-art products (using ELISA (AESKULISA®), BLOT (AESKUBLOTS®), or Immunofluorescence (AESKUSLIDES®) methodology), covering the wide area of autoimmunity, infectious serology, allergy, and food intolerance.

The high quality and innovativeness of AESKU products have their foundation in the in-house research, development, and production of all assays and lab systems. This ensures the best possible quality and consistency to the customer.

Within a short time, AESKU.DIAGNOSTICS becomes a recognized name in autoimmunity diagnostics and still offers the most comprehensive product portfolio worldwide. Acquiring DST in 2017 – a specialized company in allergy and food intolerance, with over 600 in-house developed and produced allergens – AESKU.GROUP added the expertise in allergy and food intolerance to its already wide-ranged set of talents. AESKU.BION specializes in manufacturing high-quality IFA products for clinical laboratories. The company is FDA-registered, and ISO 13485:2016 certified. They are experts in IFA for Immunology, virology, and microbiology.

After we have managed to secure a top position in international competition in many areas of laboratory and clinical diagnostics, it is an important concern for us to make this know-how available to the end-consumer directly. So we have developed and distributed the first-available SARS-CoV-2 self-test in Germany. 

In addition to our own commitment to research and development, we initiated and supported the AESKU.KIPP INSTITUTE, a non-profit organization primarily engaged in basic research and interdisciplinary knowledge transfer in the field of autoimmunity.

Our company was founded in 2000 by Dr. Torsten Matthias, a renowned scientist with over 30 years of experience in autoimmune disease research. Dr. Matthias is (co-)author of over 110 scientific publications. We currently employ more than 300 people from over 21 nations, and offer over 1,100 different products, which are distributed in over 90 countries around the world.  AESKU.GROUP has local branches in Germany, the US, Italy, UK, Singapore, Columbia, and China.